Esketamine disinhibits brain networks in depression: Evidence from oscillatory and aperiodic activity.
Verina Guirguis, Sanvi Korsapathy, Francesca Pupillo, Robert K McClure, David Zarzar, Mengsen Zhang, Flavio Frohlich, Tobias Schwippel
Progress in Neuro-Psychopharmacology and Biological Psychiatry July 5, 2025 DOI: 10.1016/j.pnpbp.2025.111438 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Individuals with major depressive disorder undergoing regular Esketamine treatment |
| Intervention | Nasal Esketamine |
| Duration | 90 minutes post-administration |
| Topics | Depression Esketamine |
| Keywords | Aperiodic exponent Brain oscillations Esketamine treatment Esketamine therapy Esketamine for depression Rapid antidepressant Brain disinhibition Neural disinhibition Brain network rebalancing Increased brain activity Mood disorder Mental health |
| Citations | 6 |
| Key findings | Esketamine induces brain network disinhibition and reduces top-down control, with neurophysiological changes closely correlating with individual drug experience. |
Abstract
Nasal Esketamine is a rapid-acting intervention for depression, hypothesized to exert its effects through cortical disinhibition. However, the spatio-temporal dynamics of brain network activity and their relationship to the subjective drug experience following Esketamine administration remain elusive. This observational study aims to delineate brain network-level effects of Esketamine by analyzing changes in oscillatory and aperiodic EEG activity within 90 min following nasal Esketamine treatment in depression. Eight individuals with major depressive disorder undergoing regular Esketamine treatment participated in the study. High-density, eyes-open resting state EEG was recorded before and subsequently five times up to 90 min post-administration. Before each recording, individuals completed ratings of individual drug experience. EEG spectral features were separated into canonical frequency bands and aperiodic exponent. Primary outcomes were changes in neural activity and their association with individual drug experience. Following Esketamine administration, we observed a marked decrease of frontoparietal alpha power and central beta and a significant increase of frontal midline delta and low gamma power, indicative of cortical disinhibition and reduction of top-down control. Correspondingly, the aperiodic exponent decreased, suggestive of a shift of the excitation/inhibition balance towards excitation. These electrophysiological changes were accompanied by an increase in subjective ratings of highness and happiness, and a decrease in tension. Further analyses revealed significant relationships between changes in neural activity and subjective drug experience. Our findings suggest that Esketamine induces brain network disinhibition and reduces top-down control. These neurophysiological changes closely correlate with individual drug experience, providing valuable insights into the neural mechanisms underlying Esketamine's immediate behavioral effects.
Comparable studies
Other observational and cohort studies on esketamine for depression, most cited first.
Citations in the library
Cited by 2
- AMPA receptor modulation in depression: from molecular mechanisms of plasticity to therapeutic translation Pharmacological Reports June 12, 2026
- Ketamine's mechanisms of action in major depressive disorder and treatment-resistant depression: Is brain topological change a candidate convergent systems-level pathway? Asian Journal of Psychiatry October 12, 2026
Cites 23
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
- Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences April 11, 2016
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
and 18 more in the library